Venus Remedies (BOM:526953) Other Stockholders Equity: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526953 Venus Remedies Ltd BOM:526953
53 GF Score
Price ₹1,676.05
GF Value ₹521.83
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Venus Remedies Other Stockholders Equity?

Venus Remedies BOM:526953 -1.29% 53 Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:526953 with a GF Score™ of 53/100 and a GF Value™ of ₹521.83 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Venus Remedies's Other Stockholders Equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

Venus Remedies's quarterly Other Stockholders Equity increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹6,504 Mil) but then declined from Mar. 2026 (₹6,504 Mil) to Jun. 2026 (₹0 Mil).

Venus Remedies's annual Other Stockholders Equity increased from Mar. 2024 (₹2,154 Mil) to Mar. 2025 (₹2,440 Mil) and increased from Mar. 2025 (₹2,440 Mil) to Mar. 2026 (₹6,504 Mil).

Venus Remedies Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Venus Remedies's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies Other Stockholders Equity Chart

Venus Remedies Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,227.27 2,165.13 2,154.23 2,439.88 6,503.80

Venus Remedies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5,809.40 0.00 6,503.80 0.00
BOM:526953
53GF Score
Venus Remedies Ltd BOM:526953
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Venus Remedies Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹0 Mil mean?
Venus Remedies (BOM:526953) has a Other Stockholders Equity of ₹0 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Venus Remedies and its competitors.
Is Venus Remedies' Other Stockholders Equity too high?
Venus Remedies' current Other Stockholders Equity is ₹0 Mil. Overall, Venus Remedies has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Venus Remedies' Other Stockholders Equity compare to ZTS and UTHR?
Venus Remedies' Other Stockholders Equity of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Venus Remedies and its competitors. Venus Remedies's current Other Stockholders Equity is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Remedies stock overvalued right now?
Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹521.83, compared to a current price of ₹1,676.05 — trading 221.2% above its estimated fair value. The current Other Stockholders Equity is ₹0 Mil. Venus Remedies' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current Other Stockholders Equity is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (BOM:526953) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,676.05 is trading 221.2% above its estimated GF Value™ of ₹521.83. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for BOM:526953:

  • Other Stockholders Equity: ₹0 Mil
  • GF Value™: ₹521.83 vs. price of ₹1,676.05 (221.2% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Remedies Business Description

Other Exchanges VENUSREM:India
Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113
Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.
53GF Score

Get the complete analysis for BOM:526953

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,676.05
Price
₹521.83
GF Value